METHOD FOR ESTIMATING CLINICAL EFFECTIVENESS OF ANTIAGGREGANT THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME Russian patent published in 2013 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: taken venous blood is separated into two samples. The first sample is stabilised with a solution of sodium citrate, the second one - with ethylene diamine tetraacetate. The first sample of whole blood is added with adenosine diphosphate as an aggregation inducer and tested for a peak amplitude of thrombocyte aggregation and a peak amplitude of adenosine triphosphate release profile by impedance method. The second sample is used to measure a fraction of thrombocytes and a fraction of blood corpuscles. It is followed by calculating a thrombocyte aggregation potential index by formula $$I=\frac{L_{\max }\cdot PTC}{{\Omega }_{\max }\cdot HTC}\cdot 100\%;$$ wherein L_max is the peak amplitude of adenosine triphosphate release profile, Ω_max is the peak amplitude of thrombocyte aggregation, PCT is the fraction of thrombocytes, HTC is the fraction of blood corpuscles. If the value I is less than 0.5%, the low clinical effectiveness of the antiaggregant therapy is stated, and the value I being 1.5-2.5% shows the high effectiveness thereof.

EFFECT: improving the objective estimation of the clinical effectiveness of the antiaggregant therapy in the patients with acute coronary syndrome, and providing an opportunity for predicting the clinical course of the disease.

1 tbl, 3 ex